References
- Daly FF, Fountain JS, Murray L, Graudins A, Buckley NA; Panel of Australian and New Zealand clinical toxicologists. Guidelines for the management of paracetamol poisoning in Australia and New Zealand–explanation and elaboration. A consensus statement from clinical toxicologists consulting to the Australasian poisons information centres. Med J Aust 2008; 188:296–301.
- Dart RC, Erdman AR, Olson KR, Christianson G, Manoguerra AS, Chyka PA, et al. Acetaminophen poisoning: an evidence-based consensus guideline for out-of-hospital management. Clin Toxicol (Phila) 2006; 44:1–18.
- Senarathna SM, Sri Ranganathan S, Buckley N, et al. A cost effectiveness analysis of the preferred antidotes for acute paracetamol poisoning patients in Sri Lanka. BMC Clin Pharmacol 2012; 12:6.
- Buckley NA, Whyte IM, O’Connell DL, Dawson AH. Oral or intravenous N-acetylcysteine: which is the treatment of choice for acetaminophen (paracetamol) poisoning?J Toxicol Clin Toxicol 1999; 37:759–767.
- Prescott LF, Illingworth RN, Critchley JA, Proudfoot AT. Intravenous N-acetylcysteine: the treatment of choice for paracetamol poisoning. Br Med J 1979; 2:1097–1100.
- Bateman DN. Controversies in the use of N-acetylcysteine as an antidote. J Toxicol Clin Toxicol 2003; 41:434–435.
- Buckley N, Eddleston M. Paracetamol (acetaminophen) poisoning. Clin Evid 2005; (14):1738–1744.
- Buckley NA, Whyte IM, O’Connell DL, Dawson AH. Activated charcoal reduces the need for N-acetylcysteine treatment after acetaminophen (paracetamol) overdose. J Toxicol Clin Toxicol 1999; 37:753–757.
- Schmidt LE, Dalhoff K, Poulsen HE. Acute versus chronic alcohol consumption in acetaminophen-induced hepatotoxicity. Hepatology 2002; 35:876–882.
- Shen F, Coulter CV, Isbister GK, Duffull SB. A dosing regimen for immediate N-acetylcysteine treatment for acute paracetamol overdose. Clin Toxicol (Phila) 2011; 49:643–647.
- Isbister GK, Kumar VV. Indications for single-dose activated charcoal administration in acute overdose. Curr Opin Crit Care 2011; 17: 351–357.
- Isbister GK. How do we use drug concentration data to improve the treatment of overdose patients?Ther Drug Monit 2010; 32: 300–304.
- Friberg LE, Isbister GK, Hackett LP, Duffull SB. The population pharmacokinetics of citalopram after deliberate self-poisoning: a bayesian approach. J Pharmacokinet Pharmacodyn 2005; 32: 571–605.
- Manini A, Smith S, Moskovitz J, Nelson L. In response to Isbister et al.: Application of pharmacokinetic-pharmacodynamic modeling in management of QT abnormalities after citalopram overdose. Intensive Care Med 2007; 33: 738; author reply 9.
- Lugassy DM, Hoffman RS, Chessex N. In response to van Gorp F. et al. Escitalopram overdose. Ann Emerg Med 2010; 55:128–129.
- Isbister GK, Friberg LE, Duffull SB. Application of pharmacokinetic-pharmacodynamic modelling in management of QT abnormalities after citalopram overdose. Intensive Care Med 2006; 32:1060–1065.
- van Gorp F, Whyte IM, Isbister GK. Clinical and ECG effects of escitalopram overdose. Ann Emerg Med 2009; 54:404–408.